NYSE
$0.1635▲ 2.77%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.5MShares out 27.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 1d agoRegular26.10.24 01:294Ownership#●●●
AIM ImmunoTech Inc.
Thomas K. Equels, an executive at AIM ImmunoTech Inc., filed a Form 4 on October 23, 2026, reporting a change in beneficial ownership of securities as of October 22, 2026. This filing serves as an official record of the insider's equity transaction.…more
$0.1635+2.77%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 05:07ARSOther
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This filing provides shareholders with an overview of the company's financial condition and business operations.…more
$0.1635+2.77%vs prev closeView filingShare - 9.30After-hours26.10.01 05:05DEF 14AOther
AIM ImmunoTech Inc.
AIM ImmunoTech Inc. will hold its 2026 Annual Meeting of Stockholders virtually on November 17, 2026, at 11:00 A.M. Eastern Time. The agenda includes the election of five directors, the ratification of BDO USA, P.C. as the independent registered public accounting firm, and an advisory vote on executive compensation.…more
$0.1635+2.77%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 22:14#●●●#●●●
AIM ImmunoTech Highlights Ampligen Strategy for Pancreatic Cancer
AIM ImmunoTech spotlighted its clinical strategy and development roadmap for its pancreatic cancer therapy, Ampligen, through a recent media feature. The update focuses on ongoing research and strategic vision rather than confirmed clinical trial results or regulatory milestones.…more
$0.1635+2.77%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Pre-market26.10.05 22:22
●●●●●●●● ●●●●● ●●●●●●
AIM ImmunoTech highlighted recent media coverage regarding the antiviral and biodefense potential of its investigational drug, Ampligen. As the announcement focuses on existing research and corporate vision without new clinical data or financial milestones, the outlook remains neutral.…more
$0.1635+2.77%vs prev close - 10.1Pre-market26.10.01 22:02
●●●●●●●● ●●●●● ●●●●●●
AIM ImmunoTech has completed dosing for its Phase 2 pancreatic cancer trial, with topline results expected in the first quarter of 2027. This update highlights ongoing clinical progress, though the company's outlook remains dependent on the upcoming trial data.…more
$0.1635+2.77%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report